These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23011220)

  • 1. Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.
    Bahar-Fuchs A; Villemagne V; Ong K; Chetélat G; Lamb F; Reininger CB; Woodward M; Rowe CC
    J Alzheimers Dis; 2013; 33(2):451-62. PubMed ID: 23011220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
    Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
    Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
    Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
    Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia.
    Spallazzi M; Michelini G; Barocco F; Dieci F; Copelli S; Messa G; Scarlattei M; Pavesi G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2020; 73(4):1647-1659. PubMed ID: 31958094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnestic Mild Cognitive Impairment.
    Tomadesso C; Perrotin A; Mutlu J; Mézenge F; Landeau B; Egret S; de la Sayette V; Jonin PY; Eustache F; Desgranges B; Chételat G
    Neuroimage Clin; 2015; 8():473-82. PubMed ID: 26106572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
    Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
    J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease?
    Lim YY; Ellis KA; Harrington K; Pietrzak RH; Gale J; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P
    J Alzheimers Dis; 2013; 33(4):1167-76. PubMed ID: 23160011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
    Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
    Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease.
    Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC
    Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.
    Lange C; Suppa P; Pietrzyk U; Makowski MR; Spies L; Peters O; Buchert R;
    J Alzheimers Dis; 2018; 61(1):373-388. PubMed ID: 29154285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology.
    Miotto EC; Brucki SMD; Cerqueira CT; Bazán PR; Silva GAA; Martin MDGM; da Silveira PS; Faria DP; Coutinho AM; Buchpiguel CA; Busatto Filho G; Nitrini R
    J Alzheimers Dis; 2022; 89(1):181-192. PubMed ID: 35871330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.